Epoxyazadiradione
Based on 1 Customer Validation
Epoxyazadiradione is a limonoid purified from neem (Azadirachta indica) fruits. Epoxyazadiradione inhibits the tautomerase activity of MIF of both human (huMIF) and malaria parasites (Plasmodium falciparum (PfMIF) and Plasmodium yoelii (PyMIF)) non-competitively in a reversible fashion (Ki, 2.11-5.23 μM). Epoxyazadiradione has the potential against proinflammatory reactions induced by MIF of both malaria parasites and human.
For research use only. We do not sell to patients.
- Purity: 99.24%
- CAS No.: 18385-59-6
- Formula: C28H34O6
- Molecular Weight:466.57
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Natural Product Library
HY-L021
-
Covalent Screening Library
HY-L036
-
Terpenoids Library
HY-L056
-
Antiparasitic Compound library
HY-L082
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Plant-Sourced Natural Product Library
HY-L115
-
Heterocyclic Compound Library
HY-L138
-
Cysteine Targeted Covalent Library
HY-L153
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
All Parasite Isoforms
More
Biological Activity
|
Plasmodium |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>20 μM
Compound: 6
|
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 21381696] |
| AZ-521 cell line | IC50 |
>20 μM
Compound: 6
|
Cytotoxicity against human AZ-521 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human AZ-521 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 21381696] |
| HL-60 | IC50 |
9.3 μM
Compound: 6
|
Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 21381696] |
| IMR-32 | IC50 |
>100 μM
Compound: 1
|
Antiproliferative activity against human IMR32 cells after 48 hrs by SRB assay
Antiproliferative activity against human IMR32 cells after 48 hrs by SRB assay
|
[PMID: 28419927] |
| MDA-MB-231 | IC50 |
>100 μM
Compound: 1
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
|
[PMID: 28419927] |
| PANC-1 | IC50 |
>100 μM
Compound: 1
|
Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay
Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay
|
[PMID: 28419927] |
| SiHa | IC50 |
>100 μM
Compound: 1
|
Antiproliferative activity against human SiHa cells after 48 hrs by SRB assay
Antiproliferative activity against human SiHa cells after 48 hrs by SRB assay
|
[PMID: 28419927] |
| SK-BR-3 | IC50 |
12.3 μM
Compound: 6
|
Cytotoxicity against human SK-BR-3 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human SK-BR-3 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 21381696] |
Chemical Information
-
CAS No. 18385-59-6
-
Appearance Solid
-
Molecular Weight 466.57
-
Formula C28H34O6
-
Color White to off-white
-
SMILES
C[C@]12[C@]34[C@]([C@@](C5=COC=C5)([H])C([C@@]3([H])O4)=O)(CC[C@]1([H])[C@@]6([C@@](C(C)(C(C=C6)=O)C)([H])C[C@H]2OC(C)=O)C)C
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : ≥ 50 mg/mL (107.17 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (2.68 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (2.68 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1433 mL | 10.7165 mL | 21.4330 mL | 53.5825 mL |
| 5 mM | 0.4287 mL | 2.1433 mL | 4.2866 mL | 10.7165 mL | |
| 10 mM | 0.2143 mL | 1.0717 mL | 2.1433 mL | 5.3583 mL | |
| 15 mM | 0.1429 mL | 0.7144 mL | 1.4289 mL | 3.5722 mL | |
| 20 mM | 0.1072 mL | 0.5358 mL | 1.0717 mL | 2.6791 mL | |
| 25 mM | 0.0857 mL | 0.4287 mL | 0.8573 mL | 2.1433 mL | |
| 30 mM | 0.0714 mL | 0.3572 mL | 0.7144 mL | 1.7861 mL | |
| 40 mM | 0.0536 mL | 0.2679 mL | 0.5358 mL | 1.3396 mL | |
| 50 mM | 0.0429 mL | 0.2143 mL | 0.4287 mL | 1.0717 mL | |
| 60 mM | 0.0357 mL | 0.1786 mL | 0.3572 mL | 0.8930 mL | |
| 80 mM | 0.0268 mL | 0.1340 mL | 0.2679 mL | 0.6698 mL | |
| 100 mM | 0.0214 mL | 0.1072 mL | 0.2143 mL | 0.5358 mL |
Epoxyazadiradione Related Classifications
HY-N10096 Related Classifications
Powered by Bioz